Your session is about to expire
← Back to Search
Stem Cell Transplant + Chemotherapy for Leukemia and Lymphoma
Study Summary
This trial is studying how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My leukemia is in partial remission, or my multiple myeloma is responding well to treatment.I am able to care for myself but cannot do normal activities or work.My heart pumps well, with an ejection fraction over 40%.Your lung function, measured by a test called DLCO, needs to be at least 40% of what is expected based on your hemoglobin levels and lung ventilation.Your doctor thinks you may have a hard time following the rules for stem cell transplantation due to serious mental health issues or difficult social circumstances.My lymphoma is currently in complete remission.I am HIV positive.Your SGOT or SGPT levels are not more than 3 times the upper limit of normal.Your bilirubin level is not more than three times the upper limit of normal.Your liver alkaline phosphatase levels are not more than three times the upper limit of normal.Your kidneys work well enough to filter out waste from your blood.It's been over 2 weeks since my last radiation or surgery, and I've followed the required waiting period after my last chemotherapy.My bone marrow has less than 5% myeloblasts.I was diagnosed with moderate to severe myelofibrosis less than 60 days ago.I have a donor match for my transplant.I am approved to undergo a specific radiation dose before a transplant.I do not have uncontrolled diabetes, heart disease, serious infections, or other conditions that would make treatment too risky.I have been diagnosed with a specific type of blood cancer or severe aplastic anemia.I am currently pregnant or breastfeeding.I have severe aplastic anemia and if I have a mismatched donor, I've been treated with ATG.I have antibodies against the transplant donor detected within the last 60 days.I had a bone marrow transplant over 6 months ago and it didn't work.
- Group 1: Prevention (chemotherapy, TBI, cyclophosphamide)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What has been the outcome of prior studies regarding Allogeneic Hematopoietic Stem Cell Transplantation?
"As of now, 1085 clinical trials for Allogeneic Hematopoietic Stem Cell Transplantation are underway worldwide. Out of those 1085 studies, 194 have advanced to Phase 3 research and the majority (30901) are hosted in Philadelphia, Pennsylvania."
What is the total enrollment capacity for this medical study?
"Yes, according to the details published on clinicaltrials.gov, this research endeavour is currently recruiting participants. It was initially announced on August 9th 2017 and last updated on May 2nd 2022; it aims to enroll 33 people at a single site."
Is enrollment for this experiment still open?
"According to the clinicaltrials.gov database, this research trial is actively looking for participants. It was first published on August 9th 2017 and its latest update occurred in May 2nd 2022."
In what medical circumstances is Allogeneic Hematopoietic Stem Cell Transplantation most frequently utilized?
"Allogeneic Hematopoietic Stem Cell Transplantation is a commonly used procedure to assist with organ transplants, as well as treating multiple sclerosis, acute leukemia and kidney transplant rejection."
What criteria must potential participants meet to join this medical experiment?
"This clinical trial seeks 33 individuals who have been diagnosed with Waldenstrom macroglobulinemia, aged between 18 and 79. In addition to this condition, the study also welcomes patients afflicted with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukaemia (CLL) ,chronic myelogenous leukaemia(CML)(including those who are intolerant or unresponsive to tyrosine kinase inhibitors, accelerated phase and blast crisis history cases); Myelodysplastic syndrome (MDS); Non-Hodgkin's Lymphoma"
Is this research accommodating geriatric patients?
"Participants in this medical trial must be aged between 18 and 79."
Share this study with friends
Copy Link
Messenger